THE TAPE
KOD · Biotechnology · $6.3B

Kodiak Sciences Inc Common Stock

$100.73▼ −9.41%
Last close
Relative strength
99RS
of 99, against every stock• 0 on the month
Powering up
Developing
+134.2%
six months against Biotechnology
52-week range
−10.7%
from the high
$18.14$112.79
Setup
vcpfresh breakout
−3.1%
against the pivot at $104.00
No report date on the calendar.
No US GAAP filings to read.
11/16 O 108.93 H 110.49 L 100.36 Vol 980.4K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS99
vs pivot−3.14%
Tightening1.59×
Dry-up2.18×
Up/down vol0.43
From high11%
failed pokefresh breakout9 of 9checks
Previous breakout stopped out ▼ −9.82% in Sep
Powering up
Support and resistance
Support below
$89.21
-11.4% · tested 3× · last 7 sessions ago
Resistance above
$103.26
+2.5% · tested 4× · last 9 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 5.4 weeks and fell 24% from its ceiling at its deepest. The pivot is $104.00, and the stock closed 3.1% below it. Its relative strength rating is 99.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+14.2%
Three months against its industry
+164.2%
Six months against its industry
+134.2%

Read against an equal-weighted index of Biotechnology, which is +22.6% against the S&P 500 over six months Partly aligned.

Also on
Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 10.8% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business

No figures in US GAAP filings for this company. Most foreign listings report under international standards, which this does not read.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Red flag in a filingFiling · 2026-11-13
going concern
No measurable effect: stocks behave like random ones over the next three sessions (1,160 cases over 54 nights).
Earnings comingEvent · 2026-11-11
reports 2026-11-12
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
GappedTape · 2026-11-10
+7.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Large insider purchaseFiling · 2026-11-07
BAKER BROS. ADVISORS LP $8,051,124
Mixed: stocks have lagged random stocks by 1.0% over three sessions, not consistently enough to call (433 cases over 55 nights). Against their own sector they have lagged by 1.0%.
GappedTape · 2026-11-07
+9.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-06
-7.6%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-10-29
+6.3%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-10-22
-5.6%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in FocusZacks Investment Research · 4 days ago

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders
Bought on the open market
86
$181,327,230 total
Sold on the open market
9
$3,538,011 total

Bought: BAKER BROS. ADVISORS LP. Sold: BORGESON JOHN A..

Not counted above: 6 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-05 BAKER BROS. ADVISORS LP · Director, 10% ownerbuy4,703$463,293
2026-11-05 BAKER BROS. ADVISORS LP · Director, 10% ownerbuy81,729$8,051,124
2026-11-04 BAKER BROS. ADVISORS LP · Director, 10% ownerbuy8,742$861,174
2026-11-04 BAKER BROS. ADVISORS LP · Director, 10% ownerbuy151,916$14,965,245
2026-10-23 Yang Taiyin · Directoroption exercise20,000$47,000
2026-10-21 BORGESON JOHN A. · Chief Financial Officeroption exercise30,000$74,700
2026-10-21 BORGESON JOHN A. · Chief Financial Officersell8,514$746,422
2026-10-21 BORGESON JOHN A. · Chief Financial Officersell1,677$149,588

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

9 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy1
Buy5
Hold1
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray
5w · 24%

The most recent of 5 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Kodiak Sciences Inc Common Stock (KOD) — The Tape